AAA
TYRA icon

Affinity Asset Advisors’s Tyra Biosciences TYRA Stock Holding History

Affinity Asset Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Sell
200,012
-57,500
-22% -$1.9M 0.29% 71
2026
Q1 		$9.86M Buy
+257,512
New +$8.34M 0.51% 50

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Affinity Asset Advisors's TYRA Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Tyra Biosciences (TYRA) stake by 22% in Q2 2026, selling an estimated $1.9M and leaving 200,012 shares worth $6.39M. The position accounts for 0.29% of the portfolio, ranked #71.

Affinity Asset Advisors first reported a position in TYRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.86M in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Affinity Asset Advisors held 200,012 shares of Tyra Biosciences worth $6.39M as of Q2 2026.
  • Affinity Asset Advisors sold 57,500 Tyra Biosciences shares in Q2 2026, an estimated $1.9M.
  • Tyra Biosciences made up 0.29% of Affinity Asset Advisors's portfolio in Q2 2026, its #71 holding.
  • Affinity Asset Advisors first reported a position in Tyra Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Affinity Asset Advisors's Tyra Biosciences position peaked at $9.86M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.